Literature DB >> 19455593

A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.

Kouki Morizono1, Yiming Xie, Gustavo Helguera, Tracy R Daniels, Timothy F Lane, Manuel L Penichet, Irvin S Y Chen.   

Abstract

BACKGROUND: Targeted gene transduction in vivo is the ultimate preferred method for gene delivery. We previously developed targeting lentiviral vectors that specifically recognize cell surface molecules with conjugated antibodies and mediate targeted gene transduction both in vitro and in vivo. Although effective in some experimental settings, the conjugation of virus with antibodies is mediated by the interaction between protein A and the Fc region of antibodies, which is not as stable as covalent conjugation. We have now developed a more stable conjugation strategy utilizing the interaction between avidin and biotin.
METHODS: We inserted the biotin-adaptor-peptide, which was biotinylated by secretory biotin ligase at specific sites, into our targeting envelope proteins, enabling conjugation of the pseudotyped virus with avidin, streptavidin or neutravidin.
RESULTS: When conjugated with avidin-antibody fusion proteins or the complex of avidin and biotinylated targeting molecules, the vectors could mediate specific transduction to targeted cells recognized by the targeting molecules. When conjugated with streptavidin-coated magnetic beads, transduction by the vectors was targeted to the locations of magnets.
CONCLUSIONS: This targeting vector system can be used for broad applications of targeted gene transduction using biotinylated targeting molecules or targeting molecules fused with avidin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455593      PMCID: PMC2834590          DOI: 10.1002/jgm.1345

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  40 in total

1.  Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.

Authors:  F Scherer; M Anton; U Schillinger; J Henke; C Bergemann; A Krüger; B Gänsbacher; C Plank
Journal:  Gene Ther       Date:  2002-01       Impact factor: 5.250

2.  A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.

Authors:  P Roux; P Jeanteur; M Piechaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Targeting a retroviral vector in the absence of a known cell-targeting ligand.

Authors:  Keith Bupp; Monica J Roth
Journal:  Hum Gene Ther       Date:  2003-11-01       Impact factor: 5.695

4.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

Review 5.  Magnetically modulated therapeutic systems.

Authors:  U O Häfeli
Journal:  Int J Pharm       Date:  2004-06-11       Impact factor: 5.875

6.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

7.  Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.

Authors:  Samuel K Campos; M Brandon Parrott; Michael A Barry
Journal:  Mol Ther       Date:  2004-06       Impact factor: 11.454

8.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

9.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

Authors:  M Brandon Parrott; Kristen E Adams; George T Mercier; Hoyin Mok; Samuel K Campos; Michael A Barry
Journal:  Mol Ther       Date:  2003-10       Impact factor: 11.454

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  28 in total

1.  Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.

Authors:  Fang Li; Byoung Y Ryu; Robin L Krueger; Scott A Heldt; Lorraine M Albritton
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  DARPins: an efficient targeting domain for lentiviral vectors.

Authors:  Robert C Münch; Michael D Mühlebach; Thomas Schaser; Sabrina Kneissl; Christian Jost; Andreas Plückthun; Klaus Cichutek; Christian J Buchholz
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

3.  Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Authors:  Kouki Morizono; Amy Ku; Yiming Xie; Airi Harui; Sam K P Kung; Michael D Roth; Benhur Lee; Irvin S Y Chen
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

4.  Role of phosphatidylserine receptors in enveloped virus infection.

Authors:  Kouki Morizono; Irvin S Y Chen
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

5.  Alleviation of Trigeminal Nociception Using p75 Neurotrophin Receptor Targeted Lentiviral Interference Therapy.

Authors:  Valerie B O'Leary; Marie O'Connell; Inga Antyborzec; Vasilis Ntziachristos; J Oliver Dolly; Saak V Ovsepian
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.

Authors:  Roshank Ahani; Farzin Roohvand; Reza Ahangari Cohan; Mohammad Hossein Etemadzadeh; Nasir Mohajel; Mahdi Behdani; Zahra Shahosseini; Navid Madani; Kayhan Azadmanesh
Journal:  Mol Biotechnol       Date:  2016-11       Impact factor: 2.695

7.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

Review 9.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

10.  Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Authors:  Xian-Yang Zhang; Robert H Kutner; Agnieszka Bialkowska; Michael P Marino; William B Klimstra; Jakob Reiser
Journal:  Retrovirology       Date:  2010-01-25       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.